Oregon Health Authority Licenses State’s First Three Facilitators for Psilocybin Services
OREGON– Oregon has become the first state in the US to implement a regulatory framework for the production of psilocybin products and the provision of psilocybin services. The state’s regulatory framework was created by M109, the Oregon Psilocybin Services Act. On April 18, the Oregon Health Authority (OHA) announced that it had licensed the first three facilitators for providing psilocybin services in the state. The OHA issued the licenses to David Naftalin, Alexander Polvi, and Jeanette Small.
The Oregon Psilocybin Services (OPS) section is part of the Oregon Health Authority Public Health Division’s Center for Health Protection. OPS adopted final rules (OAR 333-333) in December 2022 and began accepting applications for four license types in January 2023, which include facilitator licenses, service center licenses, manufacturer licenses, and laboratory licenses.
According to OPS, psilocybin administration sessions can only take place in licensed service centers statewide. These centers can employ and/or contract licensed facilitators trained to support preparation, administration, and integration sessions with clients. Service centers will provide psilocybin products produced by licensed manufacturers and tested by licensed laboratories. Currently, two manufacturers have licenses for producing psilocybin in the state. OPS anticipates issuing licenses to service center and laboratory applicants in the coming months.
“We want to congratulate the first facilitators to be licensed in Oregon,” says Oregon Psilocybin Services Section Manager Angie Allbee. “As your work in providing non-directive psilocybin services takes shape, we thank you for your dedication to client safety and access as we move closer to opening service centers.”
The OHA’s statement notes that the licensing of the facilitators for providing psilocybin services is a significant milestone for Oregon as the state moves closer to opening service centers.
Reunion Neuroscience to be Acquired by MPM BioImpact in $13.1 Million All-Cash Deal
LOS ANGELES-- Reunion Neuroscience Inc. a clinical-stage biopharmaceutical company specializing in innovative therapies for underserved mental health conditions, has announced a definitive arrangement agreement with MPM BioImpact, a leading biotechnology investment firm. Under the agreement, ...
California’s Regulated Cannabis Market Sees Decline in Sales and Tax Revenue in Q1 2023
LOS ANGELES-- California's hopes of increased consumer participation in the regulated cannabis market did not translate into a boost in licensed retail sales or state tax revenue during the first quarter of 2023. According to ...
C21 Investments Repays $30 Million Debt to CEO Sonny Newman
LOS ANGELES-- C21 Investments Inc., a vertically integrated cannabis company, announced today the successful completion of the full repayment of its $30 million senior secured note owed to Sonny Newman, the Company's President and Chief ...